Castle Biosciences(US:CSTL)2026-02-26 22:32Financial Data and Key Metrics Changes - In Q4 2025, the company reported total revenue of $87 million, leading to a full-year revenue of $344.2 million, exceeding guidance [21][30] - Excluding DecisionDx-SCC and IDgenetix revenue, the revenue growth for 2025 would have been approximately 34% [7] - The adjusted gross margin for Q4 was 76.3%, slightly up from 76.2% in Q4 2024, while the full-year gross margin was 69.2%, down from 78.5% in 2024 [22][24] - The net loss for Q4 2025 was $2.3 million, compared to a net income of $9.6 million in Q4 2024, and the full-year net loss was $24.2 million, compared to a net income of $18.2 million in 2024 [27] Business Line Data and Key Metrics Changes - The total test report volume for 2025 was 105,053, a 37% increase compared to 2024, with TissueCypher report volume growing by 86% [8][11] - DecisionDx-Melanoma delivered 39,083 test reports in 2025, reflecting a 9% year-over-year growth, while TissueCypher achieved 39,014 test reports [10][11] - The company had 2,082 new ordering clinicians for TissueCypher in 2025, up from 1,234 in 2024 [13] Market Data and Key Metrics Changes - The company reported approximately 31% patient penetration for DecisionDx-Melanoma and 11% for TissueCypher exiting 2025 [11][13] - The company is focusing on expanding its addressable market through the launch of AdvanceAD-Tx, which targets patients with moderate to severe atopic dermatitis [15] Company Strategy and Development Direction - The company aims to drive growth through its core revenue drivers, DecisionDx-Melanoma and TissueCypher, while also expanding into dermatology with AdvanceAD-Tx [10][15] - The company plans to continue evaluating M&A opportunities that align with its strategic criteria, focusing on tests that are near or at market and reimbursement [19] - The long-term growth strategy includes developing a pipeline test for GI diseases and collaborating with SciBase for EIS technology [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, emphasizing the importance of disciplined execution and innovation [6][31] - The anticipated revenue for 2026 is projected to be between $340 million and $350 million, reflecting mid to high teens growth over 2025 [21] - Management acknowledged the challenges posed by the operating environment but remains focused on improving patient care through innovative tests [9] Other Important Information - The company completed the acquisition of Previse and launched the AdvanceAD-Tx test in late 2025, which is expected to contribute materially to revenue in 2027 or 2028 [8][15] - The company had cash equivalents and marketable securities of $299.5 million as of December 31, 2025 [29] Q&A Session Summary Question: Update on DecisionDx-Melanoma and NCCN guidelines - Management noted that the NCCN guidelines did not change the threshold for sentinel lymph node biopsy, and while DecisionDx-Melanoma data supports its use, only a fraction of studies were included in the guidelines [34][36][38] Question: FDA submission timeline for DecisionDx-Melanoma - The company is preparing a de novo 510(k) submission, expecting acceptance by the end of 2026 or early 2027, which could enhance reimbursement discussions [41][43] Question: Strategy for AdvanceAD-Tx and sales team approach - The sales team is currently focused on DecisionDx-Melanoma, with plans to gradually incorporate AdvanceAD-Tx as awareness and adoption grow [47][50] Question: TissueCypher sales team and growth strategy - The company continues to expand the TissueCypher sales team and is exploring opportunities with larger group practices to enhance efficiency and volume [53][56] Question: Expectations for TissueCypher volume growth in 2026 - Management anticipates continued volume growth for TissueCypher, driven by both existing and new clinicians, although growth rates may moderate as penetration increases [71][75]